Showing 1 - 20 results of 38 for search 'S. Tolaney', query time: 0.05s
Refine Results
-
1
-
2
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer by Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Published 2022-08-01
Article -
3
How I treat HER2-low advanced breast cancer by Ilana Schlam, Sara M. Tolaney, Paolo Tarantino
Published 2023-02-01
Article -
4
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer by Sarah Sammons, Sarah Sammons, Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Sara M. Tolaney, Sara M. Tolaney, Evanthia T. Roussos Torres
Published 2023-08-01
Article -
5
-
6
-
7
-
8
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer by Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino
Published 2023-03-01
Article -
9
Immunotherapy for early triple negative breast cancer: research agenda for the next decade by Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A. Mittendorf, Hope Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice Andrè, Giuseppe Curigliano
Published 2022-02-01
Article -
10
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer by Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo
Published 2023-12-01
Article -
11
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A... by Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz-Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M. Tolaney
Published 2023-12-01
Article -
12
Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison by Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching
Published 2023-02-01
Article -
13
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan by Laura Alder, Dario Trapani, Claire Bradbury, Amanda E. D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, Christopher D. Lascola, Liangge Hsu, Nancy U. Lin, Sarah Sammons
Published 2023-03-01
Article -
14
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study by Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney
Published 2022-11-01
Article -
15
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer by Paolo Tarantino, Julieta Leone, Carlos T. Vallejo, Rachel A. Freedman, Adrienne G. Waks, Olga Martínez-Sáez, Ana Garrido-Castro, Filipa Lynce, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney, Jose P. Leone
Published 2024-04-01
Article -
16
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer by Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia
Published 2021-08-01
Article -
17
896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance by Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Sandro Santagata, Jennifer L Guerriero, Nabihah Tayob, Peter K Sorger, Madeline G Townsend, Kelly F Zheng, Kenichi Shimada, Molly DiLullo, Eileen Wrabel, Tanya Keenan, Romualdo Barroso-Sousa
Published 2023-11-01Article -
18
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen
Published 2022-10-01
Article -
19
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) by Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Michelle DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian Krop, Ann H. Partridge, Sara M. Tolaney
Published 2022-11-01
Article -
20
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer by Ana C. Garrido-Castro, Meredith M. Regan, Samuel M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. Rosenbluth, Caroline Block, Laura E. Warren, Jennifer R. Bellon, Eren Yeh, Beth T. Harrison, Elizabeth Troll, Nancy U. Lin, Sara M. Tolaney, Beth Overmoyer, Filipa Lynce
Published 2023-06-01
Article